RU2347782C2 - Производные 1-(4-бензилпиперазин-1-ил)-3-фенилпропенона и их применение, фармацевтическая композиция и способ ингибирования рецепторов хемокина (ccr-1) - Google Patents
Производные 1-(4-бензилпиперазин-1-ил)-3-фенилпропенона и их применение, фармацевтическая композиция и способ ингибирования рецепторов хемокина (ccr-1) Download PDFInfo
- Publication number
- RU2347782C2 RU2347782C2 RU2005115964/04A RU2005115964A RU2347782C2 RU 2347782 C2 RU2347782 C2 RU 2347782C2 RU 2005115964/04 A RU2005115964/04 A RU 2005115964/04A RU 2005115964 A RU2005115964 A RU 2005115964A RU 2347782 C2 RU2347782 C2 RU 2347782C2
- Authority
- RU
- Russia
- Prior art keywords
- fluorobenzyl
- chloro
- methylpiperazin
- oxopropenyl
- phenyl
- Prior art date
Links
- 0 CC(C(Cl)=O)=C* Chemical compound CC(C(Cl)=O)=C* 0.000 description 17
- OOXDZWWHAPWHLG-FNORWQNLSA-N CC(C)(C)OC(Nc1c(/C=C/C(O)=O)ccc(Cl)c1)=O Chemical compound CC(C)(C)OC(Nc1c(/C=C/C(O)=O)ccc(Cl)c1)=O OOXDZWWHAPWHLG-FNORWQNLSA-N 0.000 description 2
- KNMODONVMOQEPY-YRNVUSSQSA-N CC(CC(Cc(cc1)ccc1F)CC1)N1C(/C=C/c(cc1)c(CN(CCC2)C2=O)cc1Cl)=O Chemical compound CC(CC(Cc(cc1)ccc1F)CC1)N1C(/C=C/c(cc1)c(CN(CCC2)C2=O)cc1Cl)=O KNMODONVMOQEPY-YRNVUSSQSA-N 0.000 description 1
- HEMOCYDSMLXSDS-UXBLZVDNSA-N CC(CN(Cc(cc1)ccc1F)CC1)N1C(/C=C/c(cc1)c(CN(CC2)CCN2C(C)=O)cc1Cl)=O Chemical compound CC(CN(Cc(cc1)ccc1F)CC1)N1C(/C=C/c(cc1)c(CN(CC2)CCN2C(C)=O)cc1Cl)=O HEMOCYDSMLXSDS-UXBLZVDNSA-N 0.000 description 1
- MYBPYOMKIBOTMM-UKTHLTGXSA-N CC(CN(Cc(cc1)ccc1F)CC1)N1C(/C=C/c(ccc(Cl)c1)c1C(C(OC(C)(C)C)=O)=C)=O Chemical compound CC(CN(Cc(cc1)ccc1F)CC1)N1C(/C=C/c(ccc(Cl)c1)c1C(C(OC(C)(C)C)=O)=C)=O MYBPYOMKIBOTMM-UKTHLTGXSA-N 0.000 description 1
- PQZMOMWLGVJHGX-WEVVVXLNSA-N CC(Nc1c(/C=C/C(N(CCN2Cc(cc3)ccc3F)CC2=O)=O)ccc(Cl)c1)=O Chemical compound CC(Nc1c(/C=C/C(N(CCN2Cc(cc3)ccc3F)CC2=O)=O)ccc(Cl)c1)=O PQZMOMWLGVJHGX-WEVVVXLNSA-N 0.000 description 1
- BVAYTOQZSPCGIL-YRNVUSSQSA-N CC(Nc1sc(S(Nc2c(/C=C/C(N3CCN(Cc(cc4)ccc4F)CC3)=O)ccc(Cl)c2)(=O)=O)c(C)[n]1C)=O Chemical compound CC(Nc1sc(S(Nc2c(/C=C/C(N3CCN(Cc(cc4)ccc4F)CC3)=O)ccc(Cl)c2)(=O)=O)c(C)[n]1C)=O BVAYTOQZSPCGIL-YRNVUSSQSA-N 0.000 description 1
- BAACKGFDPMVUSD-ACCUITESSA-N CC1CC(Cc2ccc(C)cc2)CCC(CC(/C=C/c2cc(N)ccc2C)=O)C1 Chemical compound CC1CC(Cc2ccc(C)cc2)CCC(CC(/C=C/c2cc(N)ccc2C)=O)C1 BAACKGFDPMVUSD-ACCUITESSA-N 0.000 description 1
- CQVUNSWFJFHHEA-ZRDIBKRKSA-N CCCCCCCC(/C=C/c(cc1)c(C)cc1Cl)=O Chemical compound CCCCCCCC(/C=C/c(cc1)c(C)cc1Cl)=O CQVUNSWFJFHHEA-ZRDIBKRKSA-N 0.000 description 1
- NJUVJVIENFYJSP-GTKKEXAPSA-N CCN(Cc(cc1)ccc1F)C(C)CNC(/C=C/c(ccc(Cl)c1)c1C(C(OC(C)(C)C)=O)=N)=O Chemical compound CCN(Cc(cc1)ccc1F)C(C)CNC(/C=C/c(ccc(Cl)c1)c1C(C(OC(C)(C)C)=O)=N)=O NJUVJVIENFYJSP-GTKKEXAPSA-N 0.000 description 1
- JRLPEMVDPFPYPJ-UHFFFAOYSA-N CCc1ccc(C)cc1 Chemical compound CCc1ccc(C)cc1 JRLPEMVDPFPYPJ-UHFFFAOYSA-N 0.000 description 1
- JOPPRQOQIGFVRI-VMPITWQZSA-N NC(Nc1cc(nccc2)c2cc1/C=C/C(N1CCC(Cc(cc2)ccc2F)CC1)=O)=O Chemical compound NC(Nc1cc(nccc2)c2cc1/C=C/C(N1CCC(Cc(cc2)ccc2F)CC1)=O)=O JOPPRQOQIGFVRI-VMPITWQZSA-N 0.000 description 1
- QPAVPZRRQHLTKM-XBXARRHUSA-N Nc1cc(Cl)ccc1/C=C/C(N1CCN(Cc(cc2)ccc2F)CC1)=O Chemical compound Nc1cc(Cl)ccc1/C=C/C(N1CCN(Cc(cc2)ccc2F)CC1)=O QPAVPZRRQHLTKM-XBXARRHUSA-N 0.000 description 1
- IBHFALKIWLPCKL-VMPITWQZSA-N Nc1cc(nccc2)c2cc1/C=C/C(N1CCC(Cc(cc2)ccc2F)CC1)=O Chemical compound Nc1cc(nccc2)c2cc1/C=C/C(N1CCC(Cc(cc2)ccc2F)CC1)=O IBHFALKIWLPCKL-VMPITWQZSA-N 0.000 description 1
- SEGKILOUMWRNMO-UHFFFAOYSA-N O=C(CN1Cc(cc2)ccc2F)NCC1=O Chemical compound O=C(CN1Cc(cc2)ccc2F)NCC1=O SEGKILOUMWRNMO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0224917.5 | 2002-10-25 | ||
| GBGB0224917.5A GB0224917D0 (en) | 2002-10-25 | 2002-10-25 | Organic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005115964A RU2005115964A (ru) | 2006-01-27 |
| RU2347782C2 true RU2347782C2 (ru) | 2009-02-27 |
Family
ID=9946616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005115964/04A RU2347782C2 (ru) | 2002-10-25 | 2003-10-24 | Производные 1-(4-бензилпиперазин-1-ил)-3-фенилпропенона и их применение, фармацевтическая композиция и способ ингибирования рецепторов хемокина (ccr-1) |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7645760B2 (https=) |
| EP (1) | EP1558594A2 (https=) |
| JP (1) | JP2006505575A (https=) |
| KR (1) | KR20050065620A (https=) |
| CN (2) | CN100554257C (https=) |
| AR (1) | AR043055A1 (https=) |
| AU (1) | AU2003296559B2 (https=) |
| BR (1) | BR0315662A (https=) |
| CA (1) | CA2502633C (https=) |
| EC (1) | ECSP055745A (https=) |
| GB (1) | GB0224917D0 (https=) |
| MX (1) | MXPA05004348A (https=) |
| NO (1) | NO20052487L (https=) |
| PE (1) | PE20040779A1 (https=) |
| PL (1) | PL374893A1 (https=) |
| RU (1) | RU2347782C2 (https=) |
| TW (1) | TW200420545A (https=) |
| WO (1) | WO2004037796A2 (https=) |
| ZA (1) | ZA200502700B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7456184B2 (en) * | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
| SE0400441D0 (sv) | 2004-02-25 | 2004-02-25 | Active Biotech Ab | Novel Benzofurans and Indols |
| SE0400440D0 (sv) * | 2004-02-25 | 2004-02-25 | Active Biotech Ab | Novel Cinnamic Amides |
| GB0409236D0 (en) * | 2004-04-26 | 2004-05-26 | Novartis Ag | Organic compounds |
| US7777035B2 (en) | 2005-06-22 | 2010-08-17 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
| CN101007794B (zh) * | 2006-01-26 | 2010-09-01 | 中国科学院上海药物研究所 | N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途 |
| US7601844B2 (en) | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| US7615556B2 (en) | 2006-01-27 | 2009-11-10 | Bristol-Myers Squibb Company | Piperazinyl derivatives as modulators of chemokine receptor activity |
| FR2902426B1 (fr) * | 2006-06-19 | 2008-09-05 | Pierre Fabre Medicament Sa | Derives de cinnamoyl-piperazine |
| WO2008090357A2 (en) * | 2007-01-24 | 2008-07-31 | Palatin Technologies, Inc. | N, n; -substituted piperazines binding to melanocortin receptor |
| TWI433838B (zh) | 2008-06-25 | 2014-04-11 | 必治妥美雅史谷比公司 | 作為趨化因子受體活性調節劑之六氫吡啶衍生物 |
| HRP20141190T1 (hr) * | 2010-01-29 | 2015-01-30 | Otsuka Pharmaceutical Co., Ltd. | Disupstituirani derivati piridina kao antikancerogena sredstva |
| US8642622B2 (en) | 2010-06-16 | 2014-02-04 | Bristol-Myers Squibb Company | Piperidinyl compound as a modulator of chemokine receptor activity |
| ES2682217T3 (es) | 2012-08-08 | 2018-09-19 | Mitsubishi Tanabe Pharma Corporation | Método para producir un compuesto de 1,4-benzoxazina |
| US9993497B2 (en) * | 2012-12-30 | 2018-06-12 | Hadasit Medical Research Services And Development Ltd. | Use of alginate compositions in preventing or reducing liver damage caused by a hepatotoxic agent |
| AP2016009020A0 (en) * | 2013-07-18 | 2016-02-29 | Novartis Ag | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core |
| WO2015048570A2 (en) * | 2013-09-26 | 2015-04-02 | Sanford-Burnham Medical Research Institute | Ebi2 modulators |
| WO2016116875A1 (en) * | 2015-01-20 | 2016-07-28 | Novartis Ag | Pet imaging agents |
| EP4065112A4 (en) * | 2019-11-22 | 2023-12-27 | The Regents of the University of California | Taspase1 inhibitors and uses thereof |
| US20230062100A1 (en) | 2019-11-28 | 2023-03-02 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0209843A2 (en) * | 1985-07-16 | 1987-01-28 | Kanebo, Ltd. | Benzylpiperazine compound, preparation thereof, pharmaceutical composition, and use |
| RU2021269C1 (ru) * | 1988-09-28 | 1994-10-15 | Фармация Аб | Пиридил- или пиримидилсодержащие производные пиперазина или 1,4-диазациклогептана или их фармакологически активные кислотно-аддитивные соли, обладающие психотропным действием |
| RU2127732C1 (ru) * | 1992-06-25 | 1999-03-20 | Фармация и Апджон Актиеболаг | Эфиры бис-фенилпиперазинникотиновой кислоты, способ их получения (варианты), фармацевтическая композиция и способ лечения расстройств центральной нервной системы |
| JP2000086603A (ja) * | 1998-07-15 | 2000-03-28 | Yoshitomi Pharmaceut Ind Ltd | 桂皮酸アミド誘導体および３―フェニルプロピオン酸アミド誘導体 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60139646A (ja) * | 1983-12-27 | 1985-07-24 | Otsuka Pharmaceut Factory Inc | ナフタレン誘導体 |
| US5380726A (en) * | 1993-01-15 | 1995-01-10 | Ciba-Geigy Corporation | Substituted dialkylthio ethers |
| FR2725445B1 (fr) * | 1994-10-10 | 1996-10-31 | Adir | Nouveaux derives a structure 1-arylalkenyl 4-aryl alkyl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6110922A (en) * | 1998-12-29 | 2000-08-29 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
| OA12670A (en) * | 2001-10-22 | 2006-06-20 | Pfizer Prod Inc | Piperazine derivatives with ccr1 receptor antagonist activity. |
-
2002
- 2002-10-25 GB GBGB0224917.5A patent/GB0224917D0/en not_active Ceased
-
2003
- 2003-10-21 TW TW092129162A patent/TW200420545A/zh unknown
- 2003-10-23 AR ARP030103870A patent/AR043055A1/es not_active Application Discontinuation
- 2003-10-23 PE PE2003001076A patent/PE20040779A1/es not_active Application Discontinuation
- 2003-10-24 CN CNB2003801020110A patent/CN100554257C/zh not_active Expired - Fee Related
- 2003-10-24 CN CNA2009101474324A patent/CN101570517A/zh active Pending
- 2003-10-24 RU RU2005115964/04A patent/RU2347782C2/ru not_active IP Right Cessation
- 2003-10-24 EP EP03809328A patent/EP1558594A2/en not_active Withdrawn
- 2003-10-24 MX MXPA05004348A patent/MXPA05004348A/es active IP Right Grant
- 2003-10-24 KR KR1020057006954A patent/KR20050065620A/ko not_active Abandoned
- 2003-10-24 BR BR0315662-1A patent/BR0315662A/pt not_active IP Right Cessation
- 2003-10-24 AU AU2003296559A patent/AU2003296559B2/en not_active Ceased
- 2003-10-24 US US10/532,331 patent/US7645760B2/en not_active Expired - Fee Related
- 2003-10-24 PL PL03374893A patent/PL374893A1/xx not_active Application Discontinuation
- 2003-10-24 JP JP2004545990A patent/JP2006505575A/ja active Pending
- 2003-10-24 CA CA2502633A patent/CA2502633C/en not_active Expired - Fee Related
- 2003-10-24 WO PCT/EP2003/011848 patent/WO2004037796A2/en not_active Ceased
-
2005
- 2005-04-04 ZA ZA200502700A patent/ZA200502700B/en unknown
- 2005-04-25 EC EC2005005745A patent/ECSP055745A/es unknown
- 2005-05-24 NO NO20052487A patent/NO20052487L/no not_active Application Discontinuation
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0209843A2 (en) * | 1985-07-16 | 1987-01-28 | Kanebo, Ltd. | Benzylpiperazine compound, preparation thereof, pharmaceutical composition, and use |
| RU2021269C1 (ru) * | 1988-09-28 | 1994-10-15 | Фармация Аб | Пиридил- или пиримидилсодержащие производные пиперазина или 1,4-диазациклогептана или их фармакологически активные кислотно-аддитивные соли, обладающие психотропным действием |
| RU2127732C1 (ru) * | 1992-06-25 | 1999-03-20 | Фармация и Апджон Актиеболаг | Эфиры бис-фенилпиперазинникотиновой кислоты, способ их получения (варианты), фармацевтическая композиция и способ лечения расстройств центральной нервной системы |
| JP2000086603A (ja) * | 1998-07-15 | 2000-03-28 | Yoshitomi Pharmaceut Ind Ltd | 桂皮酸アミド誘導体および３―フェニルプロピオン酸アミド誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP055745A (es) | 2005-07-06 |
| WO2004037796A2 (en) | 2004-05-06 |
| US7645760B2 (en) | 2010-01-12 |
| NO20052487D0 (no) | 2005-05-24 |
| KR20050065620A (ko) | 2005-06-29 |
| RU2005115964A (ru) | 2006-01-27 |
| CA2502633C (en) | 2011-02-01 |
| CA2502633A1 (en) | 2004-05-06 |
| NO20052487L (no) | 2005-05-24 |
| WO2004037796A3 (en) | 2004-06-17 |
| AR043055A1 (es) | 2005-07-13 |
| BR0315662A (pt) | 2005-08-30 |
| TW200420545A (en) | 2004-10-16 |
| CN100554257C (zh) | 2009-10-28 |
| CN101570517A (zh) | 2009-11-04 |
| PE20040779A1 (es) | 2004-12-21 |
| EP1558594A2 (en) | 2005-08-03 |
| AU2003296559A1 (en) | 2004-05-13 |
| US20060173004A1 (en) | 2006-08-03 |
| MXPA05004348A (es) | 2005-08-02 |
| GB0224917D0 (en) | 2002-12-04 |
| CN1708489A (zh) | 2005-12-14 |
| JP2006505575A (ja) | 2006-02-16 |
| AU2003296559B2 (en) | 2007-11-01 |
| ZA200502700B (en) | 2006-05-31 |
| PL374893A1 (en) | 2005-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2347782C2 (ru) | Производные 1-(4-бензилпиперазин-1-ил)-3-фенилпропенона и их применение, фармацевтическая композиция и способ ингибирования рецепторов хемокина (ccr-1) | |
| KR101799007B1 (ko) | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 설폰아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물 | |
| AU2002344820B2 (en) | Dipeptidyl peptidase inhibitors for the treatment of diabetes | |
| DE60102710T2 (de) | Bizyklische pyrrolyl-amide als glukogen-phosphorylase-hemmer | |
| DE69719191T2 (de) | Tetrahydroisoquinoline derivate als modulatoren von dopamine d3 rezeptoren | |
| RU2669695C2 (ru) | Циклические амидные производные как ингибиторы 11-бета-гидроксистероид-дегидрогеназы и их применение | |
| JP2007536369A (ja) | プロリン及びモルホリン誘導体の新規化合物 | |
| WO2003000181A2 (en) | Dipeptidyl peptidase inhibitors for the treatment of diabetes | |
| JPH072851A (ja) | ５員複素環化合物、それらの調製方法及びこれらの化合物を含む医薬組成物 | |
| AU2002310465A1 (en) | Dipeptidyl peptidase inhibitors for the treatment of diabetes | |
| JP2004513108A (ja) | γ−セクレターゼ阻害剤としてのスルファミド | |
| CZ2004627A3 (cs) | Dibenzylaminové sloučeniny a jejich farmaceutické použití | |
| JP2007510702A (ja) | 代謝性疾患の処置に有用な１１−β−ＨＳＤ１阻害剤としてのＮ−アシル化−３−（ベンゾイル）−ピロリジン | |
| WO2008053913A1 (en) | Sulfonylurea derivative capable of selectively inhibiting mmp-13 | |
| WO2007057768A2 (en) | Sulfonyl derivatives | |
| US20050239853A1 (en) | New compounds | |
| JP2011525487A (ja) | トロンビン阻害剤としての使用のための新規複素環式カルボキサミド | |
| JP2023513121A (ja) | Ａｄａｍｔｓ阻害剤、その製造および医薬用途 | |
| US5319096A (en) | (1H-indol-1-yl)-2-(amino) acetamides and related (1H-indol-1-yl)-(aminoalkyl)amides, pharmaceutical composition and use | |
| JPH04230358A (ja) | α−メルカプトアルキルアミンの新規なＮ−置換誘導体、それらの製造法及び中間体、それらの薬剤としての使用並びにそれらを含有する組成物 | |
| JP5944483B2 (ja) | アダマンチル基を有するスルファミド誘導体及びこれの薬剤学的に許容可能な塩 | |
| US4628057A (en) | Tetrahydro-β-carboline derivatives and treatment of liver diseases | |
| JP2004519435A (ja) | 抗炎症性薬物として有用なヒダントイン化合物 | |
| JP2005306839A (ja) | 二環性ピペラジン化合物およびその用途 | |
| NZ626745B2 (en) | Cyclic amide derivatives as inhibitors of 11 - beta - hydroxysteroid dehydrogenase and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20111025 |
|
| NF4A | Reinstatement of patent |
Effective date: 20121020 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20141025 |